ZYNTEGLO is the first gene therapy approved for transfusion-dependent β-thalassemia (TDT)
European marketing authorization for ZYNTEGLO follows the fastest assessment of an advanced therapy medicinal product (ATMP) as part of the European Medicines Agency’s Priority Medicines (PRIME) program
ZYNTEGLO is bluebird bio’s first gene therapy to gain regulatory approval
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190603005497/en/
TDT is a severe genetic disease caused by mutations in the β-globin gene that result in reduced or absent hemoglobin. In order to survive, people with TDT maintain hemoglobin levels through lifelong chronic blood transfusions. These transfusions carry the risk of progressive multi-organ damage due to unavoidable iron overload. ZYNTEGLO is a one-time gene therapy that addresses the underlying genetic cause of TDT and offers patients 12 years and older who do not have a β0/β0 genotype the potential to become transfusion independent, which once achieved is expected to be life-long.
“EC approval of ZYNTEGLO is a milestone that represents the dedication
and commitment of clinical investigators, healthcare providers, patients
and their families, and our employees, all of whom have helped advance
this treatment from concept to an approved therapy,” said
ZYNTEGLO was reviewed as part of the European Medicines Agency’s (EMA) Priority Medicines (PRIME) and Adaptive Pathways programs, which support medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options. The PRIME and Adaptive Pathway programs allowed for early and enhanced dialogue and accelerated assessment of ZYNTEGLO, which was completed on the shortest timetable for an advanced therapy medicinal product (ATMP) by the EMA to date.
“As one of the investigators in the clinical studies of ZYNTEGLO, I have
witnessed firsthand the hope this gene therapy can provide to patients
and their families who have often been managing this disease and
transfusions for years, often for decades,” said Professor
ZYNTEGLO adds functional copies of a modified form of the β-globin gene (βA-T87Q-globin gene) into a patient’s own hematopoietic (blood) stem cells (HSCs). This means there is no need for donor HSCs from another person as is required for allogeneic HSC transplantation (allo-HSCT). A patient’s HSCs are removed from the body through a process called apheresis. These HSCs are taken to a lab where a lentiviral vector is used to insert the βA-T87Q-globin gene into the patient’s HSCs. This step is called transduction. Before their modified HSCs are returned through infusion, a patient receives chemotherapy to prepare their bone marrow for the modified HSCs that now carry the βA-T87Q-globin gene. Once a patient has the βA-T87Q-globin gene they have the potential to produce HbAT87Q, which is gene therapy-derived-hemoglobin, at levels that eliminate or significantly reduce the need for transfusions. Upon engraftment and achievement of transfusion independence, effects of ZYNTEGLO are expected to be life-long.
Due to the highly technical and specialized nature of administering gene therapy in rare diseases, bluebird bio is working with select qualified treatment centers that have expertise in stem cell transplant and treating patients with TDT to provide ZYNTEGLO.
The conditional marketing authorization is valid in all 28 member states
of the EU as well as
Data Supporting Clinical Profile of ZYNTEGLO
The conditional marketing authorization is supported by efficacy, safety
and durability data from the Phase 1/2 HGB-205 study and the completed
Phase 1/2 Northstar (HGB-204) study as well as available data from the
ongoing Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies,
and the long-term follow-up study LTF-303, as of the data cut off of
Data from Phase 1/2 HGB-205 showed that 75 percent (n=3/4) of patients who do not have a β0/β0 genotype achieved transfusion independence, meaning they had not received a transfusion for at least 12 months or more and maintained weighted hemoglobin ≥9 g/dL. In the Phase 1/2 Northstar study, 80 percent (n=8/10) of patients who do not have a β0/β0 genotype achieved transfusion independence.
These 11 patients (three from HGB-205 and eight from Northstar) continued to maintain transfusion independence, which at the time of data cut off was for a duration of 21–56 months.
Five patients in Northstar-2 were evaluable for transfusion independence. Of these five, 80 percent (n=4/5) achieved transfusion independence.
Non-serious adverse events (AEs) observed during clinical trials that were attributed to ZYNTEGLO were hot flush, dyspnoea, abdominal pain, pain in extremities and non-cardiac chest pain. One serious adverse event (SAE) of thrombocytopenia was considered possibly related to ZYNTEGLO.
Additional AEs observed in clinical studies were consistent with the known side effects of HSC collection and bone marrow ablation with busulfan, including SAEs of veno-occlusive disease.
For details, please see the Summary of Product Characteristics (SmPC).
ZYNTEGLO continues to be evaluated in the ongoing Phase 3 Northstar-2 and Northstar-3 studies and the long-term follow-up study LTF-303.
In addition to Priority Medicines (PRIME) designation, ZYNTEGLO received an Orphan Medicinal Product designation from the EC for the treatment of β-thalassemia intermedia and major, which includes TDT.
The U.S. Food and Drug Administration granted ZYNTEGLO Orphan Drug status and Breakthrough Therapy designation for the treatment of TDT.
About bluebird bio, Inc.
bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.
bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing.
bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com.
Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and
ZYNTEGLO and LentiGlobin are trademarks of bluebird bio.
The full common name for ZYNTEGLO: A genetically modified autologous CD34+ cell enriched population that contains hematopoietic stem cells transduced with lentiviral vector encoding the βA-T87Q-globin gene.
This release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
statements regarding the Company’s plans and expectations for the
commercialization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin
gene, formerly LentiGlobin™ in TDT) to treat TDT, and the potential
implications of clinical data for patients. Any forward-looking
statements are based on management’s current expectations of future
events and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk that the
efficacy and safety results from our prior and ongoing clinical trials
of ZYNTEGLO will not continue or be repeated in our ongoing or planned
clinical trials of ZYNTEGLO; the risk that the current or planned
clinical trials of ZYNTEGLO will be insufficient to support regulatory
submissions or marketing approval in the US, or for additional patient
populations in the EU; the risk that the production of HbAT87Q may
not be sustained over extended periods of time; and the risk that we may
not secure adequate pricing or reimbursement to support continued
development or commercialization of ZYNTEGLO following regulatory
approval. For a discussion of other risks and uncertainties, and other
important factors, any of which could cause our actual results to differ
from those contained in the forward-looking statements, see the section
entitled “Risk Factors” in our most recent Form 10-Q, as well as
discussions of potential risks, uncertainties, and other important
factors in our subsequent filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005497/en/
Source: bluebird bio
Elizabeth Pingpank, 617-914-8736
Catherine Falcetti, 339-499-9436